The Effect of Daily Valacyclovir Suppression on Herpes Simplex Virus Type 2 Viral Shedding in HSV-2 Seropositive Subjects Without a History of Genital Herpes

@article{Sperling2008TheEO,
  title={The Effect of Daily Valacyclovir Suppression on Herpes Simplex Virus Type 2 Viral Shedding in HSV-2 Seropositive Subjects Without a History of Genital Herpes},
  author={Rhoda S. Sperling and Kenneth H. Fife and Terri J Warren and Lynn P Dix and Clare A. Brennan},
  journal={Sexually Transmitted Diseases},
  year={2008},
  volume={35},
  pages={286-290}
}
Background: A substantial number of HSV-2 seropositive individuals lack a history of clinically recognized genital herpes. These individuals can transmit disease during periods of asymptomatic viral shedding. The frequency of asymptomatic shedding and the efficacy of antiviral therapy in reducing shedding has not been assessed in this population. Objective: To compare the effect of valacyclovir 1 g once daily for 60 days versus placebo on asymptomatic viral shedding in immunocompetent, HSV-2… Expand
Herpes Simplex Virus Type 2 Infection in Young Adult Women: Risk Factors for Infection and Frequency of Viral Shedding
TLDR
HSV 2 infection is very common among young adult women, but symptomatic genital herpes is not, and early intervention strategies will be needed to control HSV 1 infection. Expand
A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva.
TLDR
The HSV-1 DNA copy number was not reduced by treatment with 500 mg of valacyClovir daily or with a combination of daily valacyclovir plus twice-daily doses of aspirin over 30 days. Expand
Use of the designation “shedder” in mucosal detection of herpes simplex virus DNA involving repeated sampling
TLDR
Most HSV-2 seropositive people shed HSV from the genital mucosa, and overall shedding rates provide consistent measures regardless of the number of swabs collected, as well as dichotomisation of people into “shedder” and “non-shedders” or “high”and “low” shedders yields inferences that depend upon sampling interval length. Expand
One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients
TLDR
Famciclovir has proven efficacy and safety in the overall RGH population and many study sites either lacked prior experience in conducting clinical studies in patients with HSV infection or enrolled small numbers of patients, which may have compromised efficacy outcomes. Expand
Screening for HSV-2 infection in STD clinics and beyond: a few answers but more questions.
TLDR
Assessing implementation of routinely offered HSV-2 testing in STD clinic-based testing as a client service found that, given that persons attending STD clinics comprise only a small minority of those with sexually transmitted infection, if HSV -2 testing is to have a plausible population impact, it will need to be implemented in a broader range of programs. Expand
Mucosal Herpes Immunity and Immunopathology to Ocular and Genital Herpes Simplex Virus Infections
TLDR
The phenotypic and functional properties of innate and adaptive mucosal immune cells, their role in antiherpes immunity, and immunopathology are reviewed and the progress and limitations in developing a safe and efficient mucosal herpes vaccine are discussed. Expand
Implementation of Routine Access to Herpes Simplex Virus Type 2 Antibody Testing in a Public Health Sexually Transmitted Disease Clinic
TLDR
Improved education regarding HSV-2 and subsidized testing may be needed in the populations that have the highest prevalence in order to encourage testing, especially among the highest risk individuals. Expand
Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
TLDR
Serologic screening for genital herpes was associated with psychosocial harms, including distress and anxiety related to positive test results, and evidence from RCTs does not establish whether preventive antiviral medication for asymptomatic HSV-2 infection has benefit. Expand
Oral infections of herpes simplex virus: symptoms, diagnosis, and treatment and pathophysiology in periodontal disease
TLDR
The current review discusses Herpes Simplex Virus: Oral Infections’ Symptoms, Diagnosis, and Treatment and Pathphysiology of HerpesSimplex Virus in Periodontal Disease. Expand
Interventions for men and women with their first episode of genital herpes.
TLDR
Low quality evidence is found from two studies of oral acyclovir, when compared to placebo, reduced the duration of symptoms in individuals undergoing their first episode of genital herpes. Expand
...
1
2
...

References

SHOWING 1-10 OF 29 REFERENCES
Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
TLDR
It is demonstrated that 1 g/d of valacyclovir administered for 60 days was generally well tolerated and was an effective suppressive therapy that significantly reduced total (clinical and subclinical) HSV-2 shedding compared with placebo in immunocompetent patients diagnosed as having recurrent HSv-2 genital herpes. Expand
Suppression of Subclinical Shedding of Herpes Simplex Virus Type 2 with Acyclovir
TLDR
To determine whether acyclovir suppresses subclinical shedding of HSV-2 in the genital tract, a placebo-controlled, crossover trial of suppressive acyClovir therapy in women with recently acquired genital herpes is conducted. Expand
Famciclovir Reduces Viral Mucosal Shedding in HSV-Seropositive Persons
TLDR
Famciclovir therapy decreases genital HSV shedding in HSV-seropositive persons, especially those with a history of genital herpes, and antiviral drugs may have varying effects on symptomatic and asymptomatic viral shedding, depending on the clinical history of the disease. Expand
Once-daily valacyclovir to reduce the risk of transmission of genital herpes*
TLDR
Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant couples. Expand
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.
TLDR
HSV-2 shedding in the genital mucosa occurs much more frequently than previously appreciated and likely plays a role in the epidemic spread of genital herpes worldwide. Expand
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
TLDR
Seropositivity for HSV-2 is associated with viral shedding in the genital tract, even in subjects with no reported history of genital herpes. Expand
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
TLDR
Although the suppression of viral replication is not complete, valacyclovir and acy Clovir are highly effective in suppressing the frequency and quantity of genital HSV shedding. Expand
Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes
TLDR
PCR and then Southern blot hybridization greatly enhanced the ability to detect herpes simplex virus at the lesion site and proved to be of greater diagnostic value in assessing genital herpes than the standard culture method currently used. Expand
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.
TLDR
Declines in HSV-2 seroprevalence in the United States in 1999-2004 are shown, suggesting that the trajectory of increasing HSVs simplex virus type 1 (HSV-1) and HSVs type 2 serop revalences in theUnited States has been reversed. Expand
Herpes simplex virus type 2 in the United States, 1976 to 1994.
TLDR
Improvements in the prevention of HSV-2 infection are needed, particularly since genital ulcers may facilitate the transmission of the human immunodeficiency virus. Expand
...
1
2
3
...